Application

(+)-cis-Diltiazem hydrochloride has been used: to study its effects on diffusion and release in monolithic dispersion matrix(26) to study its neuroprotective effects in retinitis pigmentosa (RP) models(27) as an antagonist against the Cav1.2 L-type calcium channels (LTCCs)(28)

Biochem/physiol Actions

Blocks slow, or L-type Ca²⁺ channels; regulates Ca²⁺ release from intracellular stores in neutrophils; stimulates 1,4-dihydropyridine binding to Ca²⁺ channels; coronary vasodilator.

Features and Benefits

This compound was developed by Valeant. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is featured on the Calcium Channels and Cyclic Nucleotide-Gated (CNG) and Hyperpolarization Activated Cyclic Nucleotide-Gated (HCN) Channels pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

General description

Diltiazem hydrochloride is used to treat cardiovascular diseases, such as angina and hypertension. It acts as an inhibitor to cytochrome P450 3A (CYP3A). Diltiazem might be associated with maculopapular rashes, urticaria and pruritus.

Packaging

1, 5, 10 g in poly bottle